Dr. Wang has been nominated as a member of the Finance Committee for the Controlled Release Society (CRS). The overarching function of this standing committee is to provide advice to the Board on all financial matters, ensuring that the CRS will fulfill its Mission and move towards its aspirational Vision. Dr. Wang has had a long-term relationship with CRS since the 2010 Jorge Heller Postdoctoral Fellow supported by CRS. It’s a great honor to serve CRS, the leading society in the Drug Delivery field.

Tomorrow, Dr. Wang will talk at the 2021 AIChE Annual Meeting in Biotherapeutic Development and Delivery Session. The title is “Gut Organoid As a Platform for Evaluating the Delivery of Nanoparticles to Treat Gastrointestinal Diseases.” Join us to learn about organoids’ latest biotherapeutic technologies at 8:00 AM ET, Thursday, November 18, 2021. The Zoom Access Link: https://meetbreakout.zoom.us/j/92982577004?pwd=Vmt4c1ZKeitZaUZwMHpycUFUTHBxUT09

Dr. Wang will give a talk at Nanovaccines Institute on 4:00 PM Thurs., Oct. 28^th, about “Organoid as a New Platform to Develop Oral Vaccines and Nanomedicines.”

Please Join us Thurs., Oct. 28th for our @nanovax Seminar Series!

This live, virtual seminar will feature Dr. Qun Wang with @iastate @ISU_CBE

Register: https://conta.cc/3lrAWTA Learn more: https://bit.ly/3AwtKK3

The Society For Biomaterials is excited to host the 2022 Annual Meeting at the Baltimore Marriott Waterfront April 27-30, 2022, in Baltimore, MD. The “Biomaterials for Organoids” session was well-recognized in the 2021 SFB meeting and is an exciting emerging research area. In 2022, we will continue this session and promote translational research to biomaterials-mediated organoid projects’ commercial viability. You are welcome to submit your abstract at https://2022.biomaterials.org/. See you in Baltimore!

This week, at the 2021 Controlled Release Society Annual Meeting, Dr. Wang did a presentation using gut organoids as a platform for evaluating the delivery of nanoparticles to treat inflammatory bowel disease. The research took advantage of gut organoids as an ex vivo platform to evaluate nanoparticles absorption, distribution, metabolism, and excretion (ADME) screening by gut epithelial cells while focusing on the effect of particle charges. Bioengineered organoids have garnered momentum for their applications in modeling human development and disease, drug screening, and future vaccine design.

Polyethylene glycol (PEG) is a kind of polymeric material with unique hydrophilicity and electrical neutrality. PEG coating is a crucial factor to improve the biophysical and chemical properties of nanoparticles and is widely studied. Protein adherence and macrophage removal are effectively relieved due to the existence of PEG on the particles. In our recent review, Effects of Polyethylene Glycol on the Surface of Nanoparticles for Targeted Drug Delivery, we discuss the PEGylation methods of nanoparticles and related techniques that have been used to detect the PEG coverage density and thickness on the surface of the nanoparticles in recent years. Congratulations to the team!

Dr. Zahra Davoudi’s paper, “Gut Organoid as a New Platform to Study Alginate and Chitosan Mediated PLGA Nanoparticles for Drug Delivery“, has been published on Marine Drugs. In this study, the impact of surface charge on the delivery of 5-ASA loaded PLGA nanoparticles into the lumen of organoids was investigated. It was concluded that the positively charged chitosan nanoparticles were more readily transported across the epithelium into the lumen than the negatively charged alginate nanoparticles. Thus, the organoid can be utilized as an appropriate model to mimic the functions of the intestinal epithelium and can be used as a model to evaluate the benefits of nanoparticle-based drug delivery. Congratulations to the team!

It’s so happy to meet with students at the Iowa State Graduation Ceremony. Congratulations to all fellow students of the Class of 2021. Good luck with your future career!